29 completed, 6 terminated. 35 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 29, Terminated 6 |
| Phase 2 | 6 | Completed 5, Terminated 1 |
Follow Relapsing Chronic Myelogenous Leukemia: new trials by email Literature Review of Relapsing Chronic Myelogenous Leukemia trials Research Report on Relapsing Chronic Myelogenous Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 | Completed | City of Hope Medical Center | 36 | 2012-10-29 | 2024-04-02 |
| Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies therapeutic allogeneic lymphocytes - Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Phase 1 | Completed | Robert Lowsky | 16 | 2012-01-01 | 2023-11-22 |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate dasatinib, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 | Terminated | National Cancer Institute (NCI) | 4 | 2011-09-01 | 2014-04-02 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies fludarabine phosphate, methoxyamine, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Case Comprehensive Cancer Center | 20 | 2011-05-01 | 2015-08-13 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML nilotinib, imatinib mesylate, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2008-08-14 | 2017-08-10 |
| GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia GTI-2040, pharmacological study, laboratory biomarker analysis - Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2007-03-01 | 2015-12-04 |
| Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases decitabine, vorinostat, laboratory biomarker analysis - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) | Phase 1 | Completed | National Cancer Institute (NCI) | 50 | 2006-06-01 | 2013-01-07 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders vorinostat, cytarabine, etoposide - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 25 | 2006-05-01 | 2013-05-03 |
| Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes vorinostat, idarubicin, laboratory biomarker analysis - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2006-03-01 | 2013-09-30 |
| Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate dasatinib, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 48 | 2006-03-01 | 2013-02-05 |
| Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia alvocidib, vorinostat - Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2006-01-01 | 2013-04-02 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia SJG-136 - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 | Terminated | National Cancer Institute (NCI) | 25 | 2005-12-01 | 2013-09-30 |
| 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes 7-hydroxystaurosporine, perifosine, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1 | Completed | National Cancer Institute (NCI) | 30 | 2005-12-01 | 2013-09-30 |
| Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia vorinostat, isotretinoin - Childhood Acute Promyelocytic Leukemia (M3), Childhood Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 60 | 2005-08-01 | 2014-06-17 |
| Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia imatinib mesylate, temsirolimus, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 21 | 2005-04-01 | 2013-01-14 |
| SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes ispinesib, laboratory biomarker analysis, pharmacological study - Acute Undifferentiated Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 2004-12-01 | 2013-01-11 |
| Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes tanespimycin, cytarabine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Basophilic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2004-11-01 | 2013-09-30 |
Showing 20 of 35. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (29) · Leukemia, Myeloid, Acute (25) · Blast Crisis (24) · Congenital Abnormalities (19) · Leukemia, Myeloid, Accelerated Phase (16) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Leukemia, Myelomonocytic, Chronic (12) · Burkitt Lymphoma (10) · Leukemia, Myeloid, Chronic-Phase (10) · Lymphoma, Large B-Cell, Diffuse (10) · Anemia, Refractory, with Excess of Blasts (8) · Lymphoma, Follicular (8) · Lymphoma, Mantle-Cell (8) · Mycosis Fungoides (8) · Sezary Syndrome (8)
Disease Attributes (35) · Hematologic Diseases (35) · Hemic and Lymphatic Diseases (35) · Leukemia (35) · Neoplasms by Histologic Type (35) · Pathologic Processes (35) · Pathological Conditions, Signs and Symptoms (35) · Chronic Disease (34) · Leukemia, Myeloid (34) · Neoplasms (34) · Bone Marrow Diseases (33) · Immune System Diseases (29) · Immunoproliferative Disorders (29) · Leukemia, Lymphoid (29) · Lymphatic Diseases (29)
Vorinostat (5) · Cytarabine (4) · Imatinib Mesylate (4) · Cyclosporine (2) · Dasatinib (2) · Flow Cytometry (2) · Granulocyte-Macrophage Colony-Stimulating Factor (2) · Interleukin-2 (2) · Peripheral Blood Stem Cell Transplantation (2) · aldesleukin (2) · alvocidib (2) · fludarabine phosphate (2) · sargramostim (2) · 1,1'-((propane-1,3-diyl)dioxy)bis(7-methoxy-2-methylidene-1,2,3,10,11,11a-hexahydro-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5,11-dione) (1) · 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (1)
National Cancer Institute (NCI) (28) · Fred Hutchinson Cancer Center (4) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Robert Lowsky (1)
United States (35) · Canada (2) · Germany (1) · Italy (1)
Maryam Fouladi (3) · Francis Giles (2) · Jorge Cortes (2) · Richard Aplenc (2) · B. Smith (1) · Brenda Cooper (1) · Brenda Sandmaier (1) · Christopher Porter (1) · Douglas Ross (1) · Ewa Carrier (1) · Farhad Ravandi-Kashani (1) · Guillermo Garcia-Manero (1) · Gunnar Ragnarsson (1) · Ivana Gojo (1) · Jean-Pierre Issa (1)
PMID 18974373, PMID 20460644, PMID 21791475, PMID 22259028, PMID 23393050, PMID 23443507, PMID 23660685, PMID 24474568, PMID 26853648, PMID 29572391, PMID 30562587, PMID 32499241
U01CA062461 (6), P01CA018029 (4), U01CA062505 (3), U01CA097452 (3), P30CA015704 (2), U01CA062502 (2), P01CA015396 (1), P30CA046934 (1), R01CA093891 (1), R21CA112936 (1), R21CA115260 (1), U01CA062487 (1), U01CA062490 (1), U01CA062491 (1), U01CA069852 (1)